Fig. 7
ALKBH5 suppresses C-MYC, Cyclin D1, MMP-2, and MMP-9 expression by inhibiting Wnt signaling. a-c qRT-PCR to measure C-MYC, cyclin D1, MMP-2, and MMP-9 mRNA levels in transformed AsPC-1, PANC-1, and BxPC-3 cells described above. d Luciferase reporter assays in BxPC-3 and MIA Paca-2 cells showing the impact of ALKBH5 overexpression on the promoter activities of C-MYC in the absence or presence of LiCl, a Wnt signaling activator. e, f qRT-PCR to measure β-catenin mRNA levels in transformed BxPC-3, MIA Paca-2, AsPC-1, and PANC-1 cells described above. g Luciferase reporter assays showing the impact of ALKBH5 overexpression or knockdown on the promoter activities of β-catenin in BxPC-3, MIA Paca-2, AsPC-1, and PANC-1 cells. h Immunoblotting to measure WIF-1, β-catenin, C-myc, cyclin D1, MMP-2, and MMP-9 protein levels in transformed AsPC-1 and BxPC-3 cells described above. i Representative images of IHC staining for ALKBH5, WIF-1, and β-catenin in tumor sections from human PDAC specimens. j ALKBH5 protein levels were positively correlated with WIF-1 protein levels in human PDAC specimens. k ALKBH5 protein levels were negatively correlated with β-catenin protein levels in human PDAC specimens. Scale bar = 200 μm (i). The data are shown as the means ± S.D. **P <0.01; ## <0.01